ADIPOQ and metabolic dysfunction-associated steatotic liver disease: In addition to having lower levels of adiponectin, patients with NAFLD also have increased intestinal permeability and the changes in intestinal microbiota may also be the driving force for the progress of NAFLD (26–29).